Exceptional response to afatinib in a patient with persistent G719A EGFR-mutant NSCLC

We present a patient with metastatic NSCLC harboring a compound EGFR mutation with co-occurring G719A and T790M mutation. T790M mutation was treatment emergent mutation when patient was on early generation tyrosine kinase inhibitors. Initial Guardant 360 showed that G719A was the dominant clone. Fol...

Descripción completa

Detalles Bibliográficos
Autores principales: Kulkarni, Amit A, Fujioka, Naomi, Reinhardt, Lucia, Patel, Manish R, Kratzke, Robert A
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Future Medicine Ltd 2022
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024393/
https://www.ncbi.nlm.nih.gov/pubmed/35463918
http://dx.doi.org/10.2217/lmt-2021-0001

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9024393/
https://www.ncbi.nlm.nih.gov/pubmed/35463918
http://dx.doi.org/10.2217/lmt-2021-0001

Ejemplares similares